The FDA's Plan to Transform & Evolve Through Data

Facing the Quality Management Challenges for Medical Device Companies

Every year patents for branded drugs continue to expire and with each expiration, the generics market expands ever larger. As the market ...

As pharmaceutical companies introduce new therapies to the U.S. market, they respond to risk-sharing agreements (RSAs) from healthcare providers, which ...

The 2.3 percent excise tax on medical devices has been one of the more publicly controversial inclusions in the five-year-old ...

The Department of Homeland Security is currently investigating dozens of cybersecurity cases related to medical devices and their potential for ...

The first post in the Analytics in Life Sciences blog series covered New Product Development. Today, we will look at ...

Clarkston Consulting attended the Generic Pharmaceutical Association (GPhA) Annual Meeting earlier this month in Miami, Florida. This annual meeting is the ...

Requirements and Implications for the Pharmaceutical Industry

Throughout this blog series, I have asked a number of Clarkston experts to discuss several different topics with respect to ...

Over the last two years, Clarkston Consulting has released its study on Quality in Generic Pharmaceuticals. As in the past, ...

An article published this month in New York Magazine highlights the recent advancements to the regenerative medicine and medical device ...